BACKGROUND: Excess risk of cardiovascular disease occurs in effectively treated individuals with human immunodeficiency virus (HIV) infection. Although elevated plasma D-dimer levels are associated with increased morbidity and mortality, the impact of HIV infection on coagulation in vivo has not been well studied. METHODS: We measured D-dimers, antithrombin, endogenous thrombin potential (ETP; a functional measure of thrombin generation in vitro), thrombin/antithrombin complexes (TAT; a measure of thrombin generation in vivo), tissue factor, prothrombin fragment 1 + 2 (F1+2), and normalized APC sensitivity ratio (nAPCsr) in 199 HIV-positive men who were receiving antiretroviral therapy and had an undetectable HIV RNA level, in 79 HIV-positive untreated men, and in 39 uninfected controls. RESULTS: Median antithrombin levels were higher while the ETP was lower among HIV-infected adults (treated and untreated), compared with controls. There were few differences between coagulation markers in the 2 HIV groups. Compared with controls, the nAPCsr was lower in treated men and the TAT level was lower in untreated individuals. We observed little difference among measured levels of D-dimer, tissue factor, or F1+2 between HIV-infected individuals and controls. Antiretroviral therapy exposure was associated with a lower antithrombin level, a lower nAPCsr, and a lower ETP, while history of opportunistic infection was associated with a higher nAPCsr. CONCLUSIONS: HIV infection is associated with decreased thrombin generation, as measured by the ETP, and an increased antithrombin level. These data suggest that HIV infection may not be associated with increased propensity toward clotting, as has been suggested on the basis of isolated measures of D-dimer levels.
BACKGROUND: Excess risk of cardiovascular disease occurs in effectively treated individuals with human immunodeficiency virus (HIV) infection. Although elevated plasma D-dimer levels are associated with increased morbidity and mortality, the impact of HIV infection on coagulation in vivo has not been well studied. METHODS: We measured D-dimers, antithrombin, endogenous thrombin potential (ETP; a functional measure of thrombin generation in vitro), thrombin/antithrombin complexes (TAT; a measure of thrombin generation in vivo), tissue factor, prothrombin fragment 1 + 2 (F1+2), and normalized APC sensitivity ratio (nAPCsr) in 199 HIV-positive men who were receiving antiretroviral therapy and had an undetectable HIV RNA level, in 79 HIV-positive untreated men, and in 39 uninfected controls. RESULTS: Median antithrombin levels were higher while the ETP was lower among HIV-infected adults (treated and untreated), compared with controls. There were few differences between coagulation markers in the 2 HIV groups. Compared with controls, the nAPCsr was lower in treated men and the TAT level was lower in untreated individuals. We observed little difference among measured levels of D-dimer, tissue factor, or F1+2 between HIV-infected individuals and controls. Antiretroviral therapy exposure was associated with a lower antithrombin level, a lower nAPCsr, and a lower ETP, while history of opportunistic infection was associated with a higher nAPCsr. CONCLUSIONS:HIV infection is associated with decreased thrombin generation, as measured by the ETP, and an increased antithrombin level. These data suggest that HIV infection may not be associated with increased propensity toward clotting, as has been suggested on the basis of isolated measures of D-dimer levels.
Authors: Eefje Jong; Susan Louw; Eric C M van Gorp; Joost C M Meijers; Hugo ten Cate; Barry F Jacobson Journal: Thromb Haemost Date: 2010-09-30 Impact factor: 5.249
Authors: P L Lutsey; M Cushman; L M Steffen; D Green; R G Barr; D Herrington; P Ouyang; A R Folsom Journal: J Thromb Haemost Date: 2006-09-26 Impact factor: 5.824
Authors: A van Hylckama Vlieg; S C Christiansen; R Luddington; S C Cannegieter; F R Rosendaal; T P Baglin Journal: Br J Haematol Date: 2007-09 Impact factor: 6.998
Authors: Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731
Authors: Guido Tans; Astrid van Hylckama Vlieg; M Christella L G D Thomassen; Joyce Curvers; Rogier M Bertina; Jan Rosing; Frits R Rosendaal Journal: Br J Haematol Date: 2003-08 Impact factor: 6.998
Authors: Mary Cushman; Aaron R Folsom; Lu Wang; Nena Aleksic; Wayne D Rosamond; Russell P Tracy; Susan R Heckbert Journal: Blood Date: 2002-09-26 Impact factor: 22.113
Authors: Abigail Eastburn; Rebecca Scherzer; Andrew R Zolopa; Constance Benson; Russell Tracy; Tri Do; Peter Bacchetti; Michael Shlipak; Carl Grunfeld; Phyllis C Tien Journal: PLoS One Date: 2011-11-02 Impact factor: 3.240
Authors: Jessica L Montoya; Jennifer Iudicello; Hannah A Oppenheim; Pariya L Fazeli; Michael Potter; Qing Ma; Paul J Mills; Ronald J Ellis; Igor Grant; Scott L Letendre; David J Moore Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Jason V Baker; Kathleen Brummel-Ziedins; Jacqueline Neuhaus; Daniel Duprez; Nathan Cummins; David Dalmau; Jack DeHovitz; Clara Lehmann; Ann Sullivan; Ian Woolley; Lewis Kuller; James D Neaton; Russell P Tracy Journal: J Am Heart Assoc Date: 2013-07-29 Impact factor: 5.501